BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 38449852)

  • 1. Virtual Care for Patients with Advanced Well Differentiated Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET).
    Phillips WJ; Pradier M; Goodwin R; Vickers M; Asmis T
    Curr Oncol; 2024 Feb; 31(2):952-961. PubMed ID: 38392065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Affecting Survival Outcomes in Neuroendocrine Tumor of the Appendix over the Past Two Decades.
    Nagesh VK; Aguilar IK; Elias D; Mansour C; Tran HH; Bhuju R; Sethi T; Sanjeeva PRP; Rivas MG; Martinez E; Auda A; Ahmed N; Philip S; Weissman S; Sotiriadis J; Bangolo A
    Diseases; 2024 May; 12(5):. PubMed ID: 38785751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A New Online Dynamic Nomogram: Construction and Validation of a Predictive Model for Distant Metastasis Risk and Prognosis in Patients with Gastrointestinal Stromal Tumors.
    Wu H; Ding P; Wu J; Sun C; Guo H; Chen S; Lowe S; Yang P; Tian Y; Liu Y; Zhao Q
    J Gastrointest Surg; 2023 Jul; 27(7):1429-1444. PubMed ID: 37231240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
    Das S; Dasari A
    Curr Oncol Rep; 2021 Mar; 23(4):43. PubMed ID: 33719003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors, prognostic factors, and nomograms for distant metastases in patients with gastroenteropancreatic neuroendocrine tumors: a population-based study.
    Li X; Fan Y; Tong J; Lou M
    Front Endocrinol (Lausanne); 2024; 15():1264952. PubMed ID: 38449852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study.
    Wu Z; Shang G; Zhang K; Wang W; Fan M; Lin R
    Int J Surg; 2024 Apr; 110(4):2178-2186. PubMed ID: 38241384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
    JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Nomogram to Predict Individual Survival of Patients with Liver-Limited Metastases from Gastroenteropancreatic Neuroendocrine Neoplasms: A US Population-Based Cohort Analysis and Chinese Multicenter Cohort Validation Study.
    Xu G; Xiao Y; Hu H; Jin B; Wu X; Wan X; Zheng Y; Xu H; Lu X; Sang X; Ge P; Mao Y; Cai J; Zhao H; Du S
    Neuroendocrinology; 2022; 112(3):263-275. PubMed ID: 33902058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms.
    Fang C; Wang W; Feng X; Sun J; Zhang Y; Zeng Y; Wang J; Chen H; Cai M; Lin J; Chen M; Chen Y; Li Y; Li S; Chen J; Zhou Z
    Br J Cancer; 2017 Nov; 117(10):1544-1550. PubMed ID: 28949958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a nomogram for predicting the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms.
    Xie S; Li L; Wang X; Li L
    Medicine (Baltimore); 2021 Jan; 100(2):e24223. PubMed ID: 33466202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies.
    Diamantopoulos LN; Kalligeros M; Halfdanarson TR; Diamantis N; Toumpanakis C
    Biology (Basel); 2023 Jul; 12(8):. PubMed ID: 37626955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?
    Fazio N; La Salvia A
    Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101794. PubMed ID: 37414651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists.
    La Salvia A; Modica R; Rossi RE; Spada F; Rinzivillo M; Panzuto F; Faggiano A; Cinieri S; Fazio N
    Cancer Treat Rev; 2023 Jun; 117():102560. PubMed ID: 37088017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factors for Lymph Node Metastasis of Rectal Neuroendocrine Tumor and Its Prognostic Impact: A Single-Center Retrospective Analysis of 195 Cases with Radical Resection.
    Hiyoshi Y; Daitoku N; Mukai T; Nagasaki T; Yamaguchi T; Akiyoshi T; Yasue C; Chino A; Saito S; Takamatsu M; Fukunaga Y
    Ann Surg Oncol; 2023 Jul; 30(7):3944-3953. PubMed ID: 36935432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?
    Garcia-Carbonero R; Anton-Pascual B; Modrego A; Del Carmen Riesco-Martinez M; Lens-Pardo A; Carretero-Puche C; Rubio-Cuesta B; Soldevilla B
    Endocr Rev; 2023 Jul; 44(4):724-736. PubMed ID: 36879384
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.